Cardiovascular Risk with Gender‑Affirming Hormone Therapy. Canadian Diabetes & Endocrinology Today, [S. l.], v. 4, n. 2, p. 34–40, 2026. DOI: 10.58931/cdet.2026.4258. Disponível em: https://CanadianDiabetesAndEndocrinologyToday.com/article/view/4-2-Druce. Acesso em: 27 aug. 2026.